Dissolving stent could revolutionize heart disease treatment

NCT ID NCT05205499

Ongoing Disease control Sponsor: Biotyx Medical (Shenzhen) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial is testing a new type of heart stent made from iron that slowly dissolves over time. The stent also releases a drug called sirolimus to help keep the artery open. About 1,059 people with coronary artery disease are receiving this device to see if it is safe and effective at treating blocked arteries.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (a device that props open arteries and slowly releases a drug to prevent re-narrowing, then dissolves)
What this could lead to: If it works, this could offer a new treatment option for coronary artery disease that avoids permanent metal implants, potentially reducing long-term complications.
What could go wrong: This is a single-arm trial with no comparison group, so results may be less reliable. The scaffold might not dissolve as expected or could cause blood clots or other complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

Contacts and locations

Locations

Fuwai Yunnan Cardiovascular Hospital

Kunming, Yunnan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.